Meeting
2021 ASCO Annual Meeting
PF‑06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
Authors
Jordi Rodon Ahnert
The University of Texas MD Anderson Cancer Center, Houston, TX
Jordi Rodon Ahnert , Cesar Augusto Perez , Kit Man Wong , Michael L. Maitland , Frank Tsai , Jordan Berlin , Kai Hsin Liao , I-Ming Wang , Lada Markovtsova , Ira A Jacobs , Nora Cavazos , Meng Li , Anthony W. Tolcher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03854227
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3019)
DOI
10.1200/JCO.2021.39.15_suppl.3019
Abstract #
3019
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
First Author: Antoine Hollebecque
Poster
2023 ASCO Annual Meeting
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Susanna Varkey Ulahannan
Poster
2022 ASCO Annual Meeting
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
First Author: Miguel Angel Villalona-Calero
Poster
2022 ASCO Annual Meeting
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
First Author: Qing Zhou